Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald

Johnson & Johnson (NYSE:JNJ)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $215.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 44.57% from the stock’s previous close.

JNJ has been the subject of several other reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada reduced their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 17th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Stock Up 0.1 %

NYSE:JNJ opened at $148.72 on Monday. The firm has a market capitalization of $357.92 billion, a price-to-earnings ratio of 9.27, a price-to-earnings-growth ratio of 2.46 and a beta of 0.55. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The stock’s 50 day moving average price is $153.70 and its two-hundred day moving average price is $154.97.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.68 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently modified their holdings of JNJ. New Republic Capital LLC boosted its position in Johnson & Johnson by 5.1% during the 1st quarter. New Republic Capital LLC now owns 4,612 shares of the company’s stock worth $730,000 after buying an additional 223 shares during the period. Ardent Capital Management Inc. raised its position in Johnson & Johnson by 0.4% during the 1st quarter. Ardent Capital Management Inc. now owns 149,505 shares of the company’s stock worth $23,650,000 after purchasing an additional 566 shares during the last quarter. Delta Financial Advisors LLC grew its position in shares of Johnson & Johnson by 0.9% in the 1st quarter. Delta Financial Advisors LLC now owns 25,082 shares of the company’s stock valued at $3,968,000 after buying an additional 221 shares during the last quarter. Donoghue Forlines LLC increased its stake in shares of Johnson & Johnson by 26.6% in the first quarter. Donoghue Forlines LLC now owns 12,082 shares of the company’s stock valued at $1,911,000 after buying an additional 2,538 shares during the period. Finally, Comgest Global Investors S.A.S. raised its position in shares of Johnson & Johnson by 2.4% during the first quarter. Comgest Global Investors S.A.S. now owns 1,860,821 shares of the company’s stock worth $294,363,000 after acquiring an additional 44,207 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.